{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:07:26Z","timestamp":1790888846829,"version":"4.1.0"},"reference-count":112,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM103446"],"award-info":[{"award-number":["P20 GM103446"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a deficiency of one of the enzymes involved in the degradation of glycosaminoglycans. Hearing loss is a common clinical presentation in MPS. This paper reviews the literature on hearing loss for each of the seven recognized subtypes of MPS. Hearing loss was found to be common in MPS I, II, III, IVA, VI, and VII, and absent from MPS IVB and MPS IX. MPS VI presents primarily with conductive hearing loss, while the other subtypes (MPS I, MPS II, MPS III, MPS IVA, and MPS VII) can present with any type of hearing loss (conductive, sensorineural, or mixed hearing loss). The sensorineural component develops as the disease progresses, but there is no consensus on the etiology of the sensorineural component. Enzyme replacement therapy (ERT) is the most common therapy utilized for MPS, but the effects of ERT on hearing function have been inconclusive. This review highlights a need for more comprehensive and multidisciplinary research on hearing function that includes behavioral testing, objective testing, and temporal bone imaging. This information would allow for better understanding of the progression and etiology of hearing loss. Owing to the prevalence of hearing loss in MPS, early diagnosis of hearing loss and annual comprehensive audiological evaluations are recommended.<\/jats:p>","DOI":"10.3390\/diagnostics10080554","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T10:45:17Z","timestamp":1596537917000},"page":"554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions"],"prefix":"10.3390","volume":"10","author":[{"given":"Jeremy","family":"Wolfberg","sequence":"first","affiliation":[{"name":"Nemours Biomedical Research, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA"},{"name":"Department of Communication Sciences and Disorders, West Chester University, West Chester, PA 19383, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthana","family":"Chintalapati","sequence":"additional","affiliation":[{"name":"Nemours Biomedical Research, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA"},{"name":"Department of Biology, Washington University in Saint Louis, Saint Louis, MO 63130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0673-2160","authenticated-orcid":false,"given":"Shunji","family":"Tomatsu","sequence":"additional","affiliation":[{"name":"Nemours Biomedical Research, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA"},{"name":"Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA"},{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1194, Japan"},{"name":"Department of Pediatrics, Shimane University, Shimane 690-8504, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0917-6603","authenticated-orcid":false,"given":"Kyoko","family":"Nagao","sequence":"additional","affiliation":[{"name":"Nemours Biomedical Research, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA"},{"name":"College of Health Sciences, University of Delaware, Newark, DE 19716, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1440-1754.1987.tb00284.x","article-title":"The mucopolysaccharidoses","volume":"23","author":"Wraith","year":"1987","journal-title":"J. Paediatr. Child. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15786","DOI":"10.1038\/ncomms15786","article-title":"Insights into Hunter syndrome from the structure of iduronate-2-sulfatase","volume":"8","author":"Demydchuk","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/ped.12636","article-title":"Sanfilippo syndrome: Overall review","volume":"57","author":"Andrade","year":"2015","journal-title":"Pediatr. Int."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Peracha, H., Sawamoto, K., Averill, L., Kecskemethy, H., Theroux, M., Thacker, M., Nagao, K., Pizarro, C., Mackenzie, W., and Kobayashi, H. (2018). Molecular genetics and metabolism, special edition: Diagnosis, Diagnosis and prognosis of Mucopolysaccharidosis IVA. Mol. Genet. Metab.","DOI":"10.1016\/j.ymgme.2018.05.004"},{"key":"ref_5","first-page":"1","article-title":"Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB","volume":"21","author":"Shimada","year":"2015","journal-title":"JIMD Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/humu.23613","article-title":"Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene","volume":"39","author":"Tomanin","year":"2018","journal-title":"Hum. Mutat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199610033351405","article-title":"Clinical and biochemical manifestations of hyaluronidase deficiency","volume":"335","author":"Natowicz","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijporl.2005.01.017","article-title":"Otorhinolaryngological manifestations of the mucopolysaccharidoses","volume":"69","author":"Simmons","year":"2005","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.6061\/clinics\/2018\/e523","article-title":"Audiometric evaluation in individuals with mucopolysaccharidosis","volume":"73","author":"Silveira","year":"2018","journal-title":"Clin. Sao Paulo"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"110137","DOI":"10.1016\/j.ijporl.2020.110137","article-title":"Otorhinolaryngological manifestations in 61 patients with mucopolysaccharidosis","volume":"135","author":"Lenka","year":"2020","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1097\/MAO.0000000000002422","article-title":"Auditory Characteristics in Patients With Mucopolysaccharidosis","volume":"40","author":"Ahn","year":"2019","journal-title":"Otol. Neurotol. Off. Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol."},{"key":"ref_13","first-page":"267","article-title":"Management of otolaryngological manifestations in mucopolysaccharidoses: Our experience","volume":"33","author":"Mesolella","year":"2013","journal-title":"Acta Otorhinolaryngol. Ital. Organo Uff. Della Soc. Ital. Otorinolaringol. E Chir. Cerv.-Facc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ymgme.2014.02.003","article-title":"Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses","volume":"111","author":"Lin","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"ref_15","first-page":"262","article-title":"Audiological findings in children with mucopolysaccharidoses type i-iv","volume":"68","year":"2017","journal-title":"Acta Otorrinolaringol. Esp."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bjorl.2015.05.007","article-title":"Audiologic evaluations of children with mucopolysaccharidosis","volume":"82","author":"Gokdogan","year":"2016","journal-title":"Braz. J. Otorhinolaryngol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e20190006","DOI":"10.1590\/2326-4594-jiems-2019-0006","article-title":"Otorhinolaryngological Findings in Patients from Southwestern Colombia with Clinical, Enzymatic and Molecular Diagnosis of Mucopolysaccharidosis II, IV-A and VI","volume":"8","author":"Giraldo","year":"2020","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamaoto.2013.597","article-title":"Improvements in Sensorineural Hearing Loss After Cord Blood Transplant in Patients With Mucopolysaccharidosis","volume":"138","author":"Jackson","year":"2012","journal-title":"Arch. Otolaryngol. Neck Surg."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"van den Broek, B.T.A., Smit, A.L., Boelens, J.J., and van Hasselt, P.M. (2020). Hearing loss in patients with mucopolysaccharidoses-1 and -6 after hematopoietic cell transplantation: A longitudinal analysis. J. Inherit. Metab. Dis.","DOI":"10.1002\/jimd.12277"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: An international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bjorl.2015.09.006","article-title":"The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis","volume":"82","author":"Dualibi","year":"2016","journal-title":"Braz. J. Otorhinolaryngol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13023-017-0583-7","article-title":"Early disease progression of Hurler syndrome","volume":"12","author":"Kiely","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1017\/S0022215100096250","article-title":"Histopathological studies of the temporal bones in Hurler\u2019s disease [mucopolysaccharidosis (MPS) IH]","volume":"99","author":"Friedmann","year":"1985","journal-title":"J. Laryngol. Otol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/MAO.0b013e3182659cc3","article-title":"Inner ear changes in mucopolysaccharidosis type I\/Hurler syndrome","volume":"33","author":"Kariya","year":"2012","journal-title":"Otol. Neurotol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/sj.bmt.1704105","article-title":"Outcome of 27 patients with Hurler\u2019s syndrome transplanted from either related or unrelated haematopoietic stem cell sources","volume":"31","author":"Souillet","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijporl.2006.09.016","article-title":"Age-related functional and histopathological changes of the ear in the MPS I mouse","volume":"71","author":"Schachern","year":"2007","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/000348948409300115","article-title":"Mucopolysaccharidosis I-H (Hurler\u2019s syndrome) and human temporal bone histopathology","volume":"93","author":"Schachern","year":"1984","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10545-011-9378-5","article-title":"Hearing loss in patients with mucopolysaccharidosis II: Data from HOS-the Hunter Outcome Survey","volume":"35","author":"Keilmann","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13023-016-0558-0","article-title":"Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II-Hunter syndrome","volume":"12","author":"Chiong","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/ajmg.a.35498","article-title":"Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II","volume":"158","author":"Hong","year":"2012","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10545-013-9661-8","article-title":"Natural history of Sanfilippo syndrome type A","volume":"37","author":"Buhrman","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Heldermon, C.D., Hennig, A.K., Ohlemiller, K.K., Ogilvie, J.M., Herzog, E.D., Breidenbach, A., Vogler, C., Wozniak, D.F., and Sands, M.S. (2007). Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000772"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ymgme.2018.02.002","article-title":"Neurophysiology of hearing in patients with mucopolysaccharidosis type IV","volume":"123","author":"Nagao","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archotol.1977.00780260048003","article-title":"Hearing patterns in Morquio\u2019s syndrome (mucopolysaccharidosis IV)","volume":"103","author":"Riedner","year":"1977","journal-title":"Arch. Otolaryngol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0378-5955(97)00054-3","article-title":"Immunohistochemical localization of keratan sulfate in the chinchilla inner ear","volume":"109","author":"Swartz","year":"1997","journal-title":"Hear. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jimd.12028","article-title":"Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review","volume":"42","author":"Gomes","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_38","first-page":"69","article-title":"Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up","volume":"13","author":"Furujo","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10545-013-9654-7","article-title":"Galsulfase (Naglazyme(R)) therapy in infants with mucopolysaccharidosis VI","volume":"37","author":"Harmatz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ymgme.2013.02.014","article-title":"Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI","volume":"109","author":"Horovitz","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","article-title":"Clinical course of sly syndrome (mucopolysaccharidosis type VII)","volume":"53","author":"Steiner","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0378-5955(02)00341-6","article-title":"Inner ear pathology in the mucopolysaccharidosis VII mouse","volume":"169","author":"Ohlemiller","year":"2002","journal-title":"Hear. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1172\/JCI1773","article-title":"Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function","volume":"101","author":"Erway","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.V86.5.2033.bloodjournal8652033","article-title":"Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII","volume":"86","author":"Sands","year":"1995","journal-title":"Blood"},{"key":"ref_45","first-page":"438","article-title":"Pathology of the ear in murine mucopolysaccharidosis type VII. Morphologic correlates of hearing loss","volume":"71","author":"Berry","year":"1994","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10545-011-9343-3","article-title":"A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis","volume":"34","author":"Imundo","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/gim.2014.25","article-title":"The natural history of MPS I: Global perspectives from the MPS I Registry","volume":"16","author":"Beck","year":"2014","journal-title":"Genet. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kubaski, F., de Oliveira Poswar, F., Michelin-Tirelli, K., Matte, U., Horovitz, D.D., Barth, A.L., Baldo, G., Vairo, F., and Giugliani, R. (2020). Mucopolysaccharidosis Type I. Diagn. Basel Switz., 10.","DOI":"10.3390\/diagnostics10030161"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: Management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13023-020-01368-x","article-title":"Assessing the impact of the five senses on quality of life in mucopolysaccharidoses","volume":"15","author":"Giugliani","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_51","first-page":"64","article-title":"Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome","volume":"13","author":"Eisengart","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","article-title":"Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings","volume":"109","author":"Laraway","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Parini, R., and Deodato, F. (2020). Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082975"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00431-006-0316-8","article-title":"Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I","volume":"166","author":"Tokic","year":"2006","journal-title":"Eur. J. Pediatr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1750-1172-8-92","article-title":"Clinical manifestations in female carriers of mucopolysaccharidosis type II: A Spanish cross-sectional study","volume":"8","author":"Couce","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"ref_57","first-page":"290","article-title":"The importance of the otorhinolaryngologic evaluation in mucopolysaccharidosis patients","volume":"15","author":"Bicalho","year":"2011","journal-title":"Int. Arch. Otorhinolaryngol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10545-012-9563-1","article-title":"Anaesthesia and airway management in mucopolysaccharidosis","volume":"36","author":"Walker","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13052-018-0557-y","article-title":"Orthopaedic challenges for mucopolysaccharidoses","volume":"44","author":"Borgo","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.prrv.2010.10.005","article-title":"Respiratory Manifestations in Mucopolysaccharidoses","volume":"12","author":"Muhlebach","year":"2011","journal-title":"Paediatric Respir. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"ref_62","unstructured":"Kim, H., An, J.Y., Choo, O.-S., Jang, J.H., Park, H.Y., and Choung, Y.-H. (2019). Cochlear Implantation via the Transmeatal Approach in an Adolescent with Hunter Syndrome-Type II Mucopolysaccharidosis. J. Audiol. Otol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF00441361","article-title":"Sanfilippo type C disease: Clinical findings in four patients with a new variant of mucopolysaccharidosis III","volume":"130","author":"Bartsocas","year":"1979","journal-title":"Eur. J. Pediatr."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/archneur.64.11.1629","article-title":"Sanfilippo Syndrome Type D: Natural History and Identification of 3 Novel Mutations in the GNS Gene","volume":"64","author":"Jansen","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/ajmg.a.40351","article-title":"Mucopolysaccharidosis III in Taiwan: Natural history, clinical and molecular characteristics of 28 patients diagnosed during a 21-year period","volume":"176","author":"Lin","year":"2018","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13023-018-0796-4","article-title":"Epidemiology of Sanfilippo syndrome: Results of a systematic literature review","volume":"13","author":"Zelei","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2007.09.011","article-title":"Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands","volume":"93","author":"Ruijter","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_68","first-page":"E1348","article-title":"Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutationsb","volume":"31","author":"Valstar","year":"2010","journal-title":"Hum. Mutat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0387-7604(01)00242-X","article-title":"Serial magnetic resonance imaging findings in mucopolysaccharidosis IIIB (Sanfilippo\u2019s syndrome B)","volume":"23","author":"Zafeiriou","year":"2001","journal-title":"Brain Dev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11011-017-0111-4","article-title":"How close are we to therapies for Sanfilippo disease?","volume":"33","author":"Gaffke","year":"2018","journal-title":"Metab. Brain Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/8904_2012_169","article-title":"Neonatal Bone Marrow Transplantation in MPS IIIA Mice","volume":"8","author":"Lau","year":"2013","journal-title":"JIMD Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1005526628598","article-title":"Bone marrow transplantation in mucopolysaccharidosis type IIIA: A comparison of an early treated patient with his untreated sibling","volume":"22","author":"Sivakumur","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/8904_2014_350","article-title":"Early Umbilical Cord Blood-Derived Stem Cell Transplantation Does Not Prevent Neurological Deterioration in Mucopolysaccharidosis Type III","volume":"18","author":"Welling","year":"2015","journal-title":"JIMD Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ymgme.2013.06.012","article-title":"High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system","volume":"109","author":"Kim","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/gt.2013.14","article-title":"Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice","volume":"20","author":"Heldermon","year":"2013","journal-title":"Gene Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/mt.2010.17","article-title":"Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB","volume":"18","author":"Heldermon","year":"2010","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Barranger, J.A., and Cabrera-Salazar, M. (2007). Mucopolysaccharidosis IV (Morquio Syndrome; MPS IV). Lysosomal Storage Disorders, Springer US.","DOI":"10.1007\/978-0-387-70909-3"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","article-title":"International Morquio A Registry: Clinical manifestation and natural course of Morquio A disease","volume":"30","author":"Tomatsu","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","article-title":"The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects","volume":"109","author":"Harmatz","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajmg.a.36833","article-title":"International guidelines for the management and treatment of Morquio A syndrome","volume":"167","author":"Hendriksz","year":"2015","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","article-title":"Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA","volume":"110","author":"Hendriksz","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajmg.1320010205","article-title":"Morquio-like syndrome with beta galactosidase deficiency and normal hexosamine sulfatase activity: Mucopolysacchariodosis IVB","volume":"1","author":"Arbisser","year":"1977","journal-title":"Am. J. Med. Genet."},{"key":"ref_83","first-page":"80","article-title":"Bone mineral density in mucopolysaccharidosis IVB","volume":"8","author":"Kubaski","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1399-0004.1976.tb01603.x","article-title":"Spondyloepiphyseal dysplasia, corneal clouding, normal intelligence and acid \u03b2-galactosidase deficiency","volume":"9","author":"Gugler","year":"1976","journal-title":"Clin. Genet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ymgme.2018.02.011","article-title":"Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002\/MOR-100), representing 5 years of treatment","volume":"123","author":"Hendriksz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_86","first-page":"178","article-title":"Multi-domain impact of elosulfase alfa in Morquio A syndrome in the pivotal phase III trial","volume":"114","author":"Hendriksz","year":"2015","journal-title":"SI Lysosome"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/DDDT.S68562","article-title":"Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome","volume":"9","author":"Tomatsu","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_88","first-page":"76","article-title":"Elosulfase alfa enzyme replacement therapy attenuates disease progression in a non-ambulatory Japanese patient with Morquio A syndrome (case report)","volume":"13","author":"Hiramatsu","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_89","first-page":"31","article-title":"Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA","volume":"1","author":"Chinen","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2015.09.011","article-title":"Hematopoietic stem cell transplantation for Morquio A syndrome","volume":"117","author":"Yabe","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1111\/j.1742-4658.2010.07769.x","article-title":"Adeno-associated virus gene transfer in Morquio A disease\u2014Effect of promoters and sulfatase-modifying factor 1","volume":"277","author":"Tomatsu","year":"2010","journal-title":"FEBS J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41390-018-0095-8","article-title":"Tailoring the AAV2 capsid vector for bone-targeting","volume":"84","author":"Barrera","year":"2018","journal-title":"Pediatr. Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Sawamoto, K., and Tomatsu, S. (2019). Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174139"},{"key":"ref_94","first-page":"2050313X19873791","article-title":"Cochlear implantation in a patient with mucopolysaccharidosis IVA","volume":"7","author":"Nagao","year":"2019","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","article-title":"Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study","volume":"164","author":"Giugliani","year":"2014","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-019-1080-y","article-title":"Recommendations for the management of MPS VI: Systematic evidence-and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_97","unstructured":"Chintalapati, K., Tomatsu, S., Morlet, T., and Nagao, K. (2019, January 15). Longitudinal analysis of hearing loss in mucopolysaccharidosis types IV and VI. Proceedings of the 10th Annual Undergraduate Research & Service Scholar Celebratory Symposium, University of Delaware, Newark, DE, USA. Available online: https:\/\/www.urp.udel.edu\/summer-sym-pres\/longitudinal-analysis-of-hearing-loss-in-mucopolysaccharidosis-types-iv-and-vi\/."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1442-200X.1991.tb02574.x","article-title":"Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) with hearing impairment and pupillary membrane remnants","volume":"33","author":"Shigematsu","year":"1991","journal-title":"Acta Paediatrics Int."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13052-018-0561-2","article-title":"Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses","volume":"44","author":"Barone","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmd2.12039","article-title":"A rare late progression form of Sly syndrome mucopolysaccharidosis","volume":"49","author":"Guffon","year":"2019","journal-title":"JIMD Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI119322","article-title":"Murine mucopolysaccharidosis type VII: Long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation","volume":"99","author":"Sands","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1073\/pnas.90.14.6567","article-title":"A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII","volume":"90","author":"Sands","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ymgme.2020.02.009","article-title":"Vestronidase alfa: Recombinant human \u03b2-glucuronidase as an enzyme replacement therapy for MPS VII","volume":"130","author":"Cadaoas","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_104","first-page":"233","article-title":"Vestronidase Alfa: A Review in Mucopolysaccharidosis VII","volume":"33","author":"McCafferty","year":"2019","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1073\/pnas.96.11.6296","article-title":"Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX","volume":"96","author":"Salo","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/hmg\/ddn088","article-title":"A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis","volume":"17","author":"Martin","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4331\/wjbc.v6.i3.110","article-title":"Biology of hyaluronan: Insights from genetic disorders of hyaluronan metabolism","volume":"6","author":"Natowicz","year":"2015","journal-title":"World J. Biol. Chem."},{"key":"ref_108","first-page":"4316","article-title":"Skeletal and hematological anomalies in HYAL2-deficient mice: A second type of mucopolysaccharidosis IX?","volume":"22","author":"Jadin","year":"2008","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.mehy.2010.07.044","article-title":"Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?","volume":"75","author":"Narajczyk","year":"2010","journal-title":"Med. Hypotheses"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13052-018-0555-0","article-title":"ENT and mucopolysaccharidoses","volume":"44","author":"Bianchi","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Torres, D.A., Barth, A.L., Valente, M.P.M., Mello, P.P.D., and Horovitz, D.D.G. (2019). Otolaryngologists and the Early Diagnosis of Mucopolysaccharidoses: A Cross-Sectional Study. Diagn. Basel Switz., 9.","DOI":"10.3390\/diagnostics9040187"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijporl.2009.09.042","article-title":"Role of the pediatric otolaryngologist in diagnosis and management of children with mucopolysaccharidoses","volume":"74","author":"Wold","year":"2010","journal-title":"Int. J. Pediatr. Otorhinolaryngol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/8\/554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:54:10Z","timestamp":1760176450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/8\/554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":112,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["diagnostics10080554"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics10080554","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]}}}